Cargando…

The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017

BACKGROUND: Nonrheumatic valvular heart diseases (NRVDs) are some of the common and treatable cardiovascular diseases. The objective of this study was to describe the burden of NRVDs in Iran from 1990 to 2017 and to compare the findings with those from the world and in particular, the North Africa a...

Descripción completa

Detalles Bibliográficos
Autores principales: Arabloo, Jalal, Omidi, Negar, Rezapour, Aziz, Sarabi Asiabar, Ali, Mojtaba Ghorashi, Seyyed, Azari, Samad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984628/
https://www.ncbi.nlm.nih.gov/pubmed/35402692
http://dx.doi.org/10.1016/j.ijcha.2022.100956
_version_ 1784682230742777856
author Arabloo, Jalal
Omidi, Negar
Rezapour, Aziz
Sarabi Asiabar, Ali
Mojtaba Ghorashi, Seyyed
Azari, Samad
author_facet Arabloo, Jalal
Omidi, Negar
Rezapour, Aziz
Sarabi Asiabar, Ali
Mojtaba Ghorashi, Seyyed
Azari, Samad
author_sort Arabloo, Jalal
collection PubMed
description BACKGROUND: Nonrheumatic valvular heart diseases (NRVDs) are some of the common and treatable cardiovascular diseases. The objective of this study was to describe the burden of NRVDs in Iran from 1990 to 2017 and to compare the findings with those from the world and in particular, the North Africa and Middle East (NAME) region. METHODS: Using publicly available estimates from the Global Burden of Disease 2017 Study (the GBD 2017 Study) for Iran and the NAME region, we reported the years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life years (DALYs), and the prevalence for NRVDs by age group and sex between 1990 and 2017. RESULTS: There were an estimated 174,071 cases and 957 deaths from NRVDs in Iran in 2017. In addition, 1844 YLDs, 21,661 YLLs, and 23,506 DALYs were caused by NRVDs in Iran in 2017. Between 1990 and 2017, the age-standardized prevalence rate increased in Ian by 15%, the death rate by 15.3%, and DALYs by 2%. Nevertheless, in the world and the NAME region, the age-standardized rates for DALYs and deaths decreased and the age-standardized prevalence rate increased till 2017. CONCLUSIONS: The burden of NRVDs is on the rise in Iran. A reduction in the burden of NRVDs in Iran requires the development of appropriate plans to meet the health needs of patients, the decrease of the modifiable risk factors, the allocation of adequate resources for the early diagnosis and management of the diseases, and an improvement in access to treatment technologies.
format Online
Article
Text
id pubmed-8984628
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89846282022-04-07 The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017 Arabloo, Jalal Omidi, Negar Rezapour, Aziz Sarabi Asiabar, Ali Mojtaba Ghorashi, Seyyed Azari, Samad Int J Cardiol Heart Vasc Original Paper BACKGROUND: Nonrheumatic valvular heart diseases (NRVDs) are some of the common and treatable cardiovascular diseases. The objective of this study was to describe the burden of NRVDs in Iran from 1990 to 2017 and to compare the findings with those from the world and in particular, the North Africa and Middle East (NAME) region. METHODS: Using publicly available estimates from the Global Burden of Disease 2017 Study (the GBD 2017 Study) for Iran and the NAME region, we reported the years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life years (DALYs), and the prevalence for NRVDs by age group and sex between 1990 and 2017. RESULTS: There were an estimated 174,071 cases and 957 deaths from NRVDs in Iran in 2017. In addition, 1844 YLDs, 21,661 YLLs, and 23,506 DALYs were caused by NRVDs in Iran in 2017. Between 1990 and 2017, the age-standardized prevalence rate increased in Ian by 15%, the death rate by 15.3%, and DALYs by 2%. Nevertheless, in the world and the NAME region, the age-standardized rates for DALYs and deaths decreased and the age-standardized prevalence rate increased till 2017. CONCLUSIONS: The burden of NRVDs is on the rise in Iran. A reduction in the burden of NRVDs in Iran requires the development of appropriate plans to meet the health needs of patients, the decrease of the modifiable risk factors, the allocation of adequate resources for the early diagnosis and management of the diseases, and an improvement in access to treatment technologies. Elsevier 2022-01-17 /pmc/articles/PMC8984628/ /pubmed/35402692 http://dx.doi.org/10.1016/j.ijcha.2022.100956 Text en © 2022 Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Paper
Arabloo, Jalal
Omidi, Negar
Rezapour, Aziz
Sarabi Asiabar, Ali
Mojtaba Ghorashi, Seyyed
Azari, Samad
The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
title The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
title_full The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
title_fullStr The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
title_full_unstemmed The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
title_short The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017
title_sort burden of nonrheumatic valvular heart diseases in iran between 1990 and 2017: results from the global burden of disease study 2017
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984628/
https://www.ncbi.nlm.nih.gov/pubmed/35402692
http://dx.doi.org/10.1016/j.ijcha.2022.100956
work_keys_str_mv AT arabloojalal theburdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT omidinegar theburdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT rezapouraziz theburdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT sarabiasiabarali theburdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT mojtabaghorashiseyyed theburdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT azarisamad theburdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT arabloojalal burdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT omidinegar burdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT rezapouraziz burdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT sarabiasiabarali burdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT mojtabaghorashiseyyed burdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017
AT azarisamad burdenofnonrheumaticvalvularheartdiseasesiniranbetween1990and2017resultsfromtheglobalburdenofdiseasestudy2017